

**Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab)
Recombinant Antibody
Catalog # APR10594**

Specification

Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) - Product Information

Application	FC, E, FTA
Primary Accession	P06756
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	144.58 KDa

Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) - Additional Information

Target/Specificity

Integrin α V / ITGAV / CD51

Endotoxin

< 0.001EU/ μ g, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Storage

-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) - Protein Information

Name ITGAV ([HGNC:6150](#))

Function

The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase- 2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1- dependent fractalkine signaling (PubMed:23125415). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778).

target="_blank">20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 and ITGAV:ITGB6 act as receptors for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:15184403, PubMed:22278742, PubMed:28117447). ITGAV:ITGB3 acts as a receptor for CD40LG (PubMed:31331973). ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP (PubMed:10640428).

Cellular Location


Cell membrane; Single-pass type I membrane protein. Cell junction, focal adhesion


Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) - Images





Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Integrin α V / ITGAV / CD51 Reference Antibody (abituzumab) is more than 98.44% ,determined by SEC-HPLC.